Breast Cancer
Breast Cancer
ClinicalActive
Key Facts
About Menarini
Menarini is a major, privately-held European pharmaceutical company with a diversified portfolio spanning pharmaceuticals, consumer healthcare, diagnostics, and derma-aesthetic medicine. It leverages a fully integrated model from R&D to global commercial execution, with a significant strategic focus on oncology and a strong partnering heritage. The company is actively investing in advanced science to build a pipeline for serious conditions while maintaining a core commitment to its values and corporate responsibility.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Antifibrotic Therapy Program | MeCo Diagnostics | Pre-clinical |
| inPROBE for HER2 | SDS Optic | Clinical Investigation |
| ACT‑BC1 | Anthrocell | Preclinical |
| APA-1000 Breast Thermotherapy System | Medifocus | Phase III |
| Early‑Detection Breast Cancer Screening | Karkinos Healthcare | Market |
| Unnamed Breast Cancer Program | Click Therapeutics | Pilot/Phase 2 |
| Lerociclib (Lerocliclib) | Chemogenics BioPharma | Phase 3 |
| AT-017 | Asieris Pharmaceuticals | Not Specified |
| CDK2 inhibitor | Acellera | Pre-clinical |
| NP-G2-044 | Novita Pharmaceuticals | Phase 2a |
| Maveropepimut-S (MVP-S) | BioVaxys | Clinical Evaluation |
| Cannabics® BRST-33 | CNBX Pharmaceuticals | Discovery |